SII launches first made-in-India HPV vaccine for cervical cancer
New Delhi, January 24: CEO of Serum Institute of India (SII) Adar Poonawalla announced the launch of the first made-in-India Human Papillomavirus (HPV) "CERVAVAC" vaccine, for the prevention of cervical cancer on Tuesday.
The event was attended by Home Minister Amit Shah, Adar Poonawalla, and Prakash K Singh, Director of Government & Regulatory Affairs at Serum Institute of India.
"On the occasion of India's National Girl Child Day and Cervical Cancer Awareness Month, @SerumInstIndia is pleased to launch the first made-in-India HPV vaccine by the hands of our Hon'ble Home Minister Shri @AmitShah Ji. @PrakashKsingh7," Adar Poonawalla said on Twitter.
'CERVAVAC' has been developed after partnership of DBT and BIRAC with the Bill and Melinda Gates Foundation, supported by Serum Institute of India Private Limited for the indigenous development of quadrivalent vaccine through its partnership programme 'Grand Challenges India'.
Earlier this month, Dr NK Arora, chairman of the Covid working group, National Technical Advisory Group on Immunisation (NTAGI), stated that India is expected to get the HPV vaccine by April at a tenth of the cost.
Dr Arora said, "There are two or three companies which are in the process (of manufacturing the vaccine in India) but the Serum Institute of India (SII) has already got the regulators' clearance and the vaccine should be available for our patients by April or May 2023."
"The vaccine should be available soon. I don't know the exact cost yet but am given to understand that the cost of the vaccine will be one-tenth of the internationally-branded vaccine currently available," he further said.